GHK-Cu vs Palmitoyl Tripeptide-38
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Also: Matrixyl synthe'6, Matrixyl Synthe 6
Palmitoyl tripeptide-38 is the active in Sederma's Matrixyl synthe'6, a newer member of the Matrixyl family launched around 2011. It is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. It is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- GHK-Cu has stronger research evidence (Human Trials) compared to Palmitoyl Tripeptide-38 (Limited Research).
Detailed Comparison
| Attribute | GHK-Cu | Palmitoyl Tripeptide-38 |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. | The peptide is Pal-Lys-Met(O2)-Lys: lysine, an oxidized methionine (methionine sulfone) and lysine, with a palmitic acid chain attached so it can get into the outer skin more easily. The sequence is taken from connective tissue proteins (collagen VI and laminin), and the idea is the classic 'matrikine' story: small fragments of broken-down matrix proteins act as a signal telling skin cells to make more matrix. Sederma claims it boosts six components in lab tests, which is where the 'synthe'6' name comes from: collagen I, III and IV, fibronectin, hyaluronic acid and laminin-5. That is a plausible signaling mechanism, but it rests on cell culture work by the manufacturer. Whether enough peptide reaches the dermis in real skin to make a measurable difference has not been independently shown. |
| Common Dosing | 1-2 mg daily systemically, or 0.05% in cosmetic formulations Once daily | 2% of the commercial ingredient in a finished product Once or twice daily |
| Administration | Subcutaneous injection or topical application | Topical (serums, creams) |
| Typical Duration | Varies by application | About 2 months in the manufacturer's study before changes were measured; ongoing use to keep any effect |
| Best Time to Take | Evening (for skin/recovery) | Morning and/or evening, on clean skin before moisturizer |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. | There is no independent, peer-reviewed clinical trial of palmitoyl tripeptide-38 on its own that we could find. The main human data is the manufacturer's: a placebo-controlled study in 25 women aged 42 to 70 with forehead lines and crow's feet, using 2% of the Matrixyl synthe'6 ingredient for two months, with reported reductions in wrinkle measures that ranged widely between people. Sederma's launch material in 2011 described visibly smoother forehead and crow's feet wrinkles after two months but gave no published sample sizes or numbers. Where the peptide shows up in published journals, it is usually as one ingredient in a multi-ingredient serum, which cannot isolate its effect. Broader reviews of cosmetic peptides make the same point about this whole category: results are often small, short and unpublished outside company brochures. A 2026 meta-analysis of randomized peptide trials found that topical peptides overall did not produce a significant wrinkle improvement in pooled data. Bottom line: a reasonable, well-tolerated ingredient with a plausible mechanism, but expect mild changes at best and treat the percentage claims as marketing until someone outside the company repeats them. |
Frequently Asked Questions: GHK-Cu vs Palmitoyl Tripeptide-38
What is the difference between GHK-Cu and Palmitoyl Tripeptide-38?
GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. Palmitoyl Tripeptide-38 is a skin & hair peptide that palmitoyl tripeptide-38 is the active in sederma's matrixyl synthe'6, a newer member of the matrixyl family launched around 2011. it is a three-amino-acid fragment with a fatty acid tail, sold as a wrinkle 'filler from the inside' for forehead lines and crow's feet. it is a cosmetic ingredient, not a drug, and the honest picture is simple: the efficacy claims come almost entirely from the company that makes it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, GHK-Cu or Palmitoyl Tripeptide-38?
Neither is universally "better" - the choice depends on your specific goals. GHK-Cu is typically used for skin & hair purposes, while Palmitoyl Tripeptide-38 is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can GHK-Cu and Palmitoyl Tripeptide-38 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using GHK-Cu and Palmitoyl Tripeptide-38 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.